Patients with Nonvalvular Atrial Fibrillation (NVAF) will be randomized to therapy with warfarin, aspirin, or aspirin placebo and followed for 1-3 years to determine the incidence of ischemic stroke and systemic embolism and secondarily the incidence of death, transient cerebral ischemic attack, and major complications of study medication.
Showing the most recent 10 out of 1267 publications